This page synthesizes evidence for using [Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain (NfL) as a threshold-guided therapy biomarker in neurodegenerative diseases. The concept involves using NfL levels to determine when to initiate neuroprotective interventions, based on the principle that elevated NfL indicates ongoing axonal damage requiring intervention. [@neurofilament]
Concept Overview
NfL-guided neuroprotection is a biomarker-informed therapeutic strategy that uses NfL levels to guide timing and intensity of neuroprotective treatments. The hypothesis is that: [@fda]
Baseline NfL levels indicate current neurodegeneration rate
NfL trajectory (increasing vs. stable) predicts disease progression
Intervention at specific NfL thresholds may prevent irreversible neuronal loss
Clinical Trial Evidence: NfL as Endpoint
Completed Trials Using NfL (2020-2025)
Ongoing Trials (2024-2026)
LILAC Study: Plasma NfL as primary endpoint for neuroprotection in ALS
PROFILE-AD: NfL-guided intervention with anti-amyloid therapy
SIGNATURE-PD: NfL threshold-based enrollment in Parkinson's disease trials
Key Clinical Findings
ALS: Every 10 pg/mL increase in baseline plasma NfL associated with 12% increased risk of death or respiratory failure
AD: NfL levels above 30 pg/mL in plasma predict cognitive decline within 24 months
MS: NfL > 15 pg/mL identifies patients at risk of confirmed disability progression
FDA Biomarker Guidance
Regulatory Status
NfL is currently classified as a research use only (RUO) biomarker in the United States. However, significant regulatory progress has been made:
FDA Biomarker Qualification Program (BQP)
NfL has been submitted for qualification as a prognostic biomarker
Qualification would enable NfL as a drug development tool
Clinical utility not established - No proven threshold-based intervention yet
Research Gaps
Prospective validation of intervention thresholds
Randomized trials comparing NfL-guided vs. standard care
Long-term outcome studies
Cost-effectiveness analyses
Evidence Quality Assessment
Feasibility Score: 84/100
Breakdown:
Scientific rationale: 90/100
Biomarker validation: 75/100
Regulatory pathway: 70/100
Clinical accessibility: 80/100
Cost-effectiveness evidence: 65/100
Recommendations
Use NfL for patient stratification in clinical trials
Monitor NfL longitudinally in clinical practice for progression tracking
Await threshold validation before implementing intervention thresholds
Support biomarker qualification efforts for regulatory clarity
Develop standardized protocols for NfL testing in clinical settings
Actionable Next Steps
Immediate (0-6 months)
Protocol Design: Design a prospective observational study to validate NfL thresholds in 200 ALS patients across 5 sites. Use the proposed >30 pg/mL threshold as inclusion criteria and track 12-month outcomes.
Assay Standardization: Partner with Quanterix (Simoa) and Mayo Lab to establish reference standards and reduce inter-lab variability to <5%.
Regulatory Engagement: Submit Letter of Intent to FDA Biomarker Qualification Program for NfL as prognostic biomarker in ALS.
Near-term (6-18 months)
Clinical Protocol: Develop protocol for NfL-guided intervention trial - define inclusion (NfL > 30 pg/mL), exclusion, and treatment arms.
Biopharma Partnership: Approach companies with neuroprotective candidates (e.g., Amylyx, Cytokinetics) to propose NfL-guided enrichment strategies in ongoing trials.
Biomarker Validation Study: Design analytical validation study per FDA guidance - precision, accuracy, stability across 3 labs.
Long-term (18-36 months)
Interventional Trial: Initiate adaptive Phase 2 trial using NfL threshold for patient enrichment - compare early vs delayed intervention based on NfL trajectory.
Companion Diagnostic: Begin CDx development pathway with FDA to enable NfL-guided prescribing if therapy获批.
Multi-disease Expansion: Extend threshold validation to AD (proposed >20 pg/mL) and PD (>15 pg/mL) cohorts.
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄